Quantifying the Prevalence and Determinants of RSV Vaccine Hesitancy in US Adults Aged 60 or Older

Matt Motta, Timothy Callaghan, Jennifer Ross, Medini Padmanabhan, Lisa Gargano, Sarah Bowman and David Vincent Yokum
Additional contact information
Matt Motta: Boston University School of Public Health
David Vincent Yokum: North Carolina

No ezaur_v1, SocArXiv from Center for Open Science

Abstract: In May 2023, federal regulators authorized two vaccines designed to prevent infection with Respiratory Syncytial Virus (RSV) for adults aged 60 or older. While some efforts have been made to study the prevalence of vaccine uptake thus far, few have studied this group’s intentions to vaccinate, as well as socio-demographic barriers to vaccination. In a nationally representative survey of N = 1,200 US Adults (N = 362 aged 60+), we find that a majority of seniors (53%) intend to refuse an RSV vaccine. As of late Fall 2023, just 14% of those eligible have already received a RSV vaccine. We also present multivariate evidence that vaccine safety and efficacy attitudes, as well as previous vaccination behaviors, are associated with RSV vaccination intentions.

Date: 2024-01-10
New Economics Papers: this item is included in nep-age and nep-hea
References: Add references at CitEc
Citations:

Downloads: (external link)
https://osf.io/download/659c5a93f8bd910e15e4a74b/

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:osf:socarx:ezaur_v1

DOI: 10.31219/osf.io/ezaur_v1

Access Statistics for this paper

More papers in SocArXiv from Center for Open Science
Bibliographic data for series maintained by OSF ().